{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:05:19Z","timestamp":1790363119417,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The aim of this study was to retrospectively evaluate the effects of conventional transarterial chemoembolization (cTACE) for the treatment of hepatocellular carcinoma over 20 years regarding overall survival (OS) and prognostic factors for OS. During the period from 1996 to 2016, 836 patients with HCC were treated with cTACE. Data evaluation was performed on the basis of pre- and postinterventional MRI and CT scans. Survival analysis was performed by Kaplan\u2013Meier estimator; prognostic factors were determined by the use of Cox regression analysis. Overall, 4084 (mean 4.89 TACE sessions\/patient) procedures were assessed. Median OS was 700 days (99% CI, 632.8\u2013767.2). Depending on the indication, patients treated with a neoadjuvant intention showed the best OS (1229 days, 99% CI 983.8\u20131474.2) followed by curative intention (787 days, 99% CI 696.3\u2013877.7), and then palliative intention (360 days, 99% CI 328.4\u2013391.6). Portal vein thrombosis (HR 2.19, CI 1.63\u20132.96, and p &lt; 0.01) and Child\u2013Pugh class B or worse (HR 1.44, CI 1.11\u20131.86, and p &lt; 0.001) were significantly associated with shorter OS. Patients with HCC benefit from TACE after careful patient selection. Portal vein thrombosis and Child\u2013Pugh class B or worse are significantly unfavorable prognostic factors for patients\u2019 survival.<\/jats:p>","DOI":"10.3390\/cancers16081498","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T03:56:13Z","timestamp":1713153373000},"page":"1498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Retrospective Long-Term Evaluation of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma over 20 Years"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-1075","authenticated-orcid":false,"given":"Thomas J.","family":"Vogl","sequence":"first","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-3398","authenticated-orcid":false,"given":"Hamzah","family":"Adwan","sequence":"additional","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Wolff","sequence":"additional","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-5227","authenticated-orcid":false,"given":"Maximilian","family":"Lahrsow","sequence":"additional","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Gruber-Rouh","sequence":"additional","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-1685","authenticated-orcid":false,"given":"Nour-Eldin Abdelrehim","family":"Nour-Eldin","sequence":"additional","affiliation":[{"name":"Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"},{"name":"Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Cairo University, Cairo 12613, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-8145","authenticated-orcid":false,"given":"Wolf-Otto","family":"Bechstein","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagy N. N.","family":"Naguib","sequence":"additional","affiliation":[{"name":"Radiology Department, AMEOS Hospital Halberstadt, 38820 Halberstadt, Germany"},{"name":"Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: A review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"key":"ref_5","first-page":"e19274","article-title":"Hepatocellular Carcinoma in 2021: An Exhaustive Update","volume":"13","author":"Philips","year":"2021","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cld.111","article-title":"Risk factors for hepatocellular carcinoma","volume":"1","author":"Herbst","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","article-title":"Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J. Carcinog."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Shimamura, T., Goto, R., Watanabe, M., Kawamura, N., and Takada, Y. (2022). Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?. Cancers, 14.","DOI":"10.3390\/cancers14020419"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lurje, I., Czigany, Z., Bednarsch, J., Roderburg, C., Isfort, P., Neumann, U.P., and Lurje, G. (2019). Treatment Strategies for Hepatocellular Carcinoma\u2014A Multidisciplinary Approach. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061465"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-2007-963285","article-title":"Transarterial chemoembolization (TACE) in hepatocellular carcinoma: Technique, indication and results]","volume":"179","author":"Vogl","year":"2007","journal-title":"RoFo Fortschritte Geb. Rontgenstrahlen Nukl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10620-019-05542-5","article-title":"HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer","volume":"64","author":"Vogl","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","first-page":"1167","article-title":"Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors","volume":"91","author":"Zhao","year":"2011","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3348\/kjr.2013.14.4.626","article-title":"Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: Comparison with surgical resection","volume":"14","author":"Kim","year":"2013","journal-title":"Korean J. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial","volume":"31","author":"Peng","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s40880-015-0023-9","article-title":"Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma","volume":"34","author":"Li","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"ref_17","first-page":"219","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Diagn. Interv. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2126992","DOI":"10.1001\/jamanetworkopen.2021.26992","article-title":"Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110006","DOI":"10.1016\/j.ejrad.2021.110006","article-title":"Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma: What is the right treatment sequence?","volume":"144","author":"Hendriks","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"978614","DOI":"10.3389\/fonc.2022.978614","article-title":"Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival","volume":"12","author":"Sun","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.21037\/tgh.2017.11.18","article-title":"Downstaging for hepatocellular cancer: Harm or benefit?","volume":"2","author":"Bryce","year":"2017","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.aohep.2020.10.006","article-title":"Standardization of conventional chemoembolization for hepatocellular carcinoma","volume":"22","author":"Renzulli","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000525500","article-title":"Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302","volume":"11","author":"Ikeda","year":"2022","journal-title":"Liver Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.23725","article-title":"Loco-regional treatment of hepatocellular carcinoma","volume":"52","author":"Lencioni","year":"2010","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4254\/wjh.v9.i18.808","article-title":"Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma","volume":"9","author":"Song","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/00016925309136722","article-title":"Catheter replacement of the needle in percutaneous arteriography; a new technique","volume":"39","author":"Seldinger","year":"1953","journal-title":"Acta Radiol."},{"key":"ref_27","first-page":"2155","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"vii41","DOI":"10.1093\/annonc\/mds225","article-title":"Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Verslype","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e11872","DOI":"10.1097\/MD.0000000000011872","article-title":"Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma","volume":"97","author":"Kong","year":"2018","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.31557\/APJCP.2022.23.9.3173","article-title":"Comparison of Overall Survival between Transarterial Chemoembolization and Best Supportive Care in Intermediate- Stage Hepatocellular Carcinoma","volume":"23","author":"Akarapatima","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared with Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fonc.2020.01205","article-title":"Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma with Macroscopic Vascular Invasion","volume":"10","author":"Su","year":"2020","journal-title":"Front Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/02656736.2022.2048095","article-title":"Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: A systematic review and meta-analysis","volume":"39","author":"Yang","year":"2022","journal-title":"Int. J. Hyperth."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/lt.24169","article-title":"Downstaging hepatocellular carcinoma: A systematic review and pooled analysis","volume":"21","author":"Parikh","year":"2015","journal-title":"Liver Transpl."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7314\/APJCP.2012.13.3.1039","article-title":"Prospective study on the survival of HCC patients treated with transcatheter arterial lipiodol chemoembolization","volume":"13","author":"Mao","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.3748\/wjg.v19.i23.3649","article-title":"Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities","volume":"19","author":"Wu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_37","first-page":"5171","article-title":"Predictors of long-term survival in hepatocellular carcinomas: A longitudinal follow-up of 108 patients with small tumors","volume":"33","author":"Chang","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liu, L., Zhang, C., Zhao, Y., Qi, X., Chen, H., Bai, W., He, C., Guo, W., Yin, Z., and Fan, D. (2014). Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: Prognostic factors in a single-center study of 188 patients. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/194278"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:27:47Z","timestamp":1760106467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,14]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081498"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081498","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,14]]}}}